Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003317070 | SCV004021148 | uncertain significance | not specified | 2023-06-13 | criteria provided, single submitter | clinical testing | Variant summary: VPS13B c.4480_4482delCTT (p.Leu1494del) results in an in-frame deletion that is predicted to remove 1 amino acid from the encoded protein. The variant was absent in 251054 control chromosomes. p.Leu1494del has been reported in the literature in two related individuals affected with Cohen Syndrome who were homozygous for the variant, but carried another pathogenic upstream truncating variant on one allele, allowing evaluation of the variant in the compound heterozygous state only (Seifert_2008). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as VUS - possibly pathogenic. |
Juha Muilu Group; Institute for Molecular Medicine Finland |
RCV000050079 | SCV000082488 | probable-pathogenic | Cohen syndrome | no assertion criteria provided | not provided | Converted during submission to Likely pathogenic. |